间歇血糖监测对1型糖尿病儿童不同胰岛素使用模式代谢控制的影响

IF 3 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Rocio Porcel-Chacón, Leopoldo Tapia-Ceballos, Ana-Belen Ariza-Jimenez, Ana Gómez-Perea, José Manuel Jiménez-Hinojosa, Juan-Pedro López-Siguero, Isabel Leiva-Gea
{"title":"间歇血糖监测对1型糖尿病儿童不同胰岛素使用模式代谢控制的影响","authors":"Rocio Porcel-Chacón, Leopoldo Tapia-Ceballos, Ana-Belen Ariza-Jimenez, Ana Gómez-Perea, José Manuel Jiménez-Hinojosa, Juan-Pedro López-Siguero, Isabel Leiva-Gea","doi":"10.3390/diseases13080254","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In healthcare centers with limited resources, or for patients who prefer to make continuous changes in their treatment themselves and do not want to rely solely on technology, intermittent glucose monitoring (isCGM) with an insulin pump is a viable option that warrants further study.</p><p><strong>Material and methods: </strong>prospective single-center study that collected data at 3 months and after isCGM implantation in pediatric patients with Type 1 diabetes, categorized according to their insulin regimen.</p><p><strong>Results: </strong>We found statistically significant differences in the time in range (TIR) between 70 and 180 mg/dl at 3 months after using the sensor (<i>p</i> = 0.017), although these differences were not maintained at 1 year (<i>p</i> = 0.064). When stricter TIRs (70-140 mg/dl) were analyzed, statistically significant differences were observed at 3 months (<i>p</i> = 0.01) and at 1 year (<i>p</i> = 0.018) in favor of patients using CSII. While 75% of the patients in the CSII group had good control with HbA1c < 7% after one year of sensor use, only 34.6% in the MDI group achieved these values. However, the CSII group presented a higher coefficient of variation (62.31% at 3 months and 43.08% at 1 year) (<i>p</i> = 0.02), and a higher number of hypoglycemic episodes (7.38% and 7.32%, respectively) (<i>p</i> = 0.016). The CSII group also had a higher number of capillary blood glucose measurements at the beginning of the study (8.32/day) (<i>p</i> = 0.249), but this number became similar between both groups after one year.</p><p><strong>Conclusions: </strong>We found statistically significant differences in favor of CSII over MDI in terms of metabolic control after one year of isCGM use. However, the TIR values were still below the range considered to be indicative of good control. These findings lead us to question whether CSII should be initially considered in specific cases where HCL is not possible, or if it would be more effective to wait until the patient is ready, or the necessary resources are available to start directly CSII integrated in a closed loop system.</p>","PeriodicalId":72832,"journal":{"name":"Diseases (Basel, Switzerland)","volume":"13 8","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12385850/pdf/","citationCount":"0","resultStr":"{\"title\":\"Differences in Metabolic Control Between Different Insulin Use Patterns in Pediatric Patients with Type 1 Diabetes Through Intermittent Glucose Monitoring.\",\"authors\":\"Rocio Porcel-Chacón, Leopoldo Tapia-Ceballos, Ana-Belen Ariza-Jimenez, Ana Gómez-Perea, José Manuel Jiménez-Hinojosa, Juan-Pedro López-Siguero, Isabel Leiva-Gea\",\"doi\":\"10.3390/diseases13080254\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>In healthcare centers with limited resources, or for patients who prefer to make continuous changes in their treatment themselves and do not want to rely solely on technology, intermittent glucose monitoring (isCGM) with an insulin pump is a viable option that warrants further study.</p><p><strong>Material and methods: </strong>prospective single-center study that collected data at 3 months and after isCGM implantation in pediatric patients with Type 1 diabetes, categorized according to their insulin regimen.</p><p><strong>Results: </strong>We found statistically significant differences in the time in range (TIR) between 70 and 180 mg/dl at 3 months after using the sensor (<i>p</i> = 0.017), although these differences were not maintained at 1 year (<i>p</i> = 0.064). When stricter TIRs (70-140 mg/dl) were analyzed, statistically significant differences were observed at 3 months (<i>p</i> = 0.01) and at 1 year (<i>p</i> = 0.018) in favor of patients using CSII. While 75% of the patients in the CSII group had good control with HbA1c < 7% after one year of sensor use, only 34.6% in the MDI group achieved these values. However, the CSII group presented a higher coefficient of variation (62.31% at 3 months and 43.08% at 1 year) (<i>p</i> = 0.02), and a higher number of hypoglycemic episodes (7.38% and 7.32%, respectively) (<i>p</i> = 0.016). The CSII group also had a higher number of capillary blood glucose measurements at the beginning of the study (8.32/day) (<i>p</i> = 0.249), but this number became similar between both groups after one year.</p><p><strong>Conclusions: </strong>We found statistically significant differences in favor of CSII over MDI in terms of metabolic control after one year of isCGM use. However, the TIR values were still below the range considered to be indicative of good control. These findings lead us to question whether CSII should be initially considered in specific cases where HCL is not possible, or if it would be more effective to wait until the patient is ready, or the necessary resources are available to start directly CSII integrated in a closed loop system.</p>\",\"PeriodicalId\":72832,\"journal\":{\"name\":\"Diseases (Basel, Switzerland)\",\"volume\":\"13 8\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-08-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12385850/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diseases (Basel, Switzerland)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/diseases13080254\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diseases (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/diseases13080254","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

在资源有限的医疗保健中心,或者对于那些喜欢自己不断改变治疗方法而不想仅仅依靠技术的患者,胰岛素泵间歇血糖监测(isCGM)是一种可行的选择,值得进一步研究。材料和方法:前瞻性单中心研究,收集1型糖尿病儿童患者isCGM植入后3个月的数据,根据胰岛素治疗方案进行分类。结果:我们发现在使用传感器3个月后,70和180 mg/dl的范围内时间(TIR)有统计学意义上的差异(p = 0.017),尽管这些差异在1年后没有保持(p = 0.064)。当分析更严格的TIRs (70-140 mg/dl)时,采用CSII的患者在3个月(p = 0.01)和1年(p = 0.018)时观察到具有统计学意义的差异。CSII组75%的患者在使用传感器一年后控制良好,HbA1c < 7%,而MDI组只有34.6%的患者达到这些值。然而,CSII组的变异系数更高(3个月时为62.31%,1年为43.08%)(p = 0.02),低血糖发作次数更高(分别为7.38%和7.32%)(p = 0.016)。CSII组在研究开始时也有较高的毛细血管血糖测量次数(8.32/天)(p = 0.249),但一年后两组之间的这个数字变得相似。结论:我们发现在使用isCGM一年后,CSII与MDI在代谢控制方面存在统计学上的显著差异。然而,TIR值仍然低于被认为是良好控制的指示范围。这些发现让我们质疑,是否应该在不可能发生HCL的特定病例中首先考虑CSII,或者等到患者准备好,或者有必要的资源可以直接在闭环系统中启动CSII会更有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Differences in Metabolic Control Between Different Insulin Use Patterns in Pediatric Patients with Type 1 Diabetes Through Intermittent Glucose Monitoring.

Introduction: In healthcare centers with limited resources, or for patients who prefer to make continuous changes in their treatment themselves and do not want to rely solely on technology, intermittent glucose monitoring (isCGM) with an insulin pump is a viable option that warrants further study.

Material and methods: prospective single-center study that collected data at 3 months and after isCGM implantation in pediatric patients with Type 1 diabetes, categorized according to their insulin regimen.

Results: We found statistically significant differences in the time in range (TIR) between 70 and 180 mg/dl at 3 months after using the sensor (p = 0.017), although these differences were not maintained at 1 year (p = 0.064). When stricter TIRs (70-140 mg/dl) were analyzed, statistically significant differences were observed at 3 months (p = 0.01) and at 1 year (p = 0.018) in favor of patients using CSII. While 75% of the patients in the CSII group had good control with HbA1c < 7% after one year of sensor use, only 34.6% in the MDI group achieved these values. However, the CSII group presented a higher coefficient of variation (62.31% at 3 months and 43.08% at 1 year) (p = 0.02), and a higher number of hypoglycemic episodes (7.38% and 7.32%, respectively) (p = 0.016). The CSII group also had a higher number of capillary blood glucose measurements at the beginning of the study (8.32/day) (p = 0.249), but this number became similar between both groups after one year.

Conclusions: We found statistically significant differences in favor of CSII over MDI in terms of metabolic control after one year of isCGM use. However, the TIR values were still below the range considered to be indicative of good control. These findings lead us to question whether CSII should be initially considered in specific cases where HCL is not possible, or if it would be more effective to wait until the patient is ready, or the necessary resources are available to start directly CSII integrated in a closed loop system.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
0
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信